Japan OKs Roche's Avastin for aggressive brain cancer

Roche has obtained approval from the Japanese Ministry of Health, Labour and Welfare to market Avastin, or bevacizumab, as a treatment for malignant glioma, including newly diagnosed glioblastoma, in combination with radiotherapy and temozolomide, and as a monotherapy for recurrent GBM and certain kinds of high-grade glioma. The approval makes Avastin the first globally approved drug for newly diagnosed glioblastoma.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL